-
Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, and Sallberg M. 2005. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocyte by DNA vaccine-primed cytotoxic T lymphocyte. J Infec Dis, 192(12): 2112-2116.
doi: 10.1086/jid.2005.192.issue-12
-
Ahlen G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, and Sällberg M. 2007. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol, 179(7) : 4741-4753.
doi: 10.4049/jimmunol.179.7.4741
-
Andre S, Seed B, Eberle J, Schraut W, Bültmann A, and Haas J. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol, 72(2): 1497-1503.
-
Arribillaga L, de Cerio A L, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borrás-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, and Lasarte J J. 2002. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV recombinant vaccinia virus. Vaccine, 21: 202-210.
doi: 10.1016/S0264-410X(02)00456-5
-
Bartenschlager R, Ahlborn-Laake L, Mous J, and Jacobsen H. 1993. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol, 67: 3835-3844.
-
Bocher W O, Dekel B, Schwerin W, Geissler M, Hoffmann S, Rohwer A, Arditti F, Cooper A, Bernhard H, Berrebi A, Rose-John S, Shaul Y, Galle P R, F Löhr H, and Reisner Y. 2001. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol, 31: 2071-2079.
doi: 10.1002/(ISSN)1521-4141
-
De Francesco R, Tomei L, Altamura S, Summa V, and Migliaccio G. 2003. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA dependent RNA polymerase. J Antiviral Res, 58(1):1-16.
doi: 10.1016/S0166-3542(03)00028-7
-
Encke J, zuPutlitz J, Geissler M, and R Wands J. 1998. Genetic Immunization generates cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model. J Immunol, 1 (61) : 4917-4923.
-
Feltquate D M, Heaney S, Webster R G, and Robinson H L. 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 158: 2278-2284.
-
Foy E, Li K, Sumpter R, Loo Y M, Johnson C L, Wang C, Fish P M, Yoneyama M, Fujita T, Lemon S M, and Gale M Jr. 2004. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS, 102 (8): 2986-2991.
-
Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, and Sällberg M. 2004. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. J Gene Ther, 11(6): 522-533.
doi: 10.1038/sj.gt.3302184
-
Frick D N. 2007. The hepatitis C virus NS3 protein: a model RNA helicase andpotential drug target. Curr Issues Mol Biol, 9 (1):1-20.
-
Gao M, Wang H P, Wang Y N, Zhou Y, and Wang Q L. 2006. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+ Th1 cell responses in vivo. Vaccine, 24: 5491-5497.
doi: 10.1016/j.vaccine.2006.04.004
-
Geissler M, Gesien A, Tokushige K, and Wands J R. 1997. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine expressing plasmids. J Immunol, 158:1231-1237.
-
Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi M, and Ebtekar E. 2007. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. J Comp immunol microbiol Infect Dis, 30(4):197-210.
doi: 10.1016/j.cimid.2007.01.002
-
Ghaemi A, Soleimanjahi H, Gill P, Zuhair H, Razeghi M, Jahromi S, and Roohvand F. 2010. Recombinant λ-phage nanobioparticles for tumor therapy in mice models. J Genet Vaccines Ther, 8(3): 1-7.
-
Ghaemi A, Soleimanjahi H, Gill P, Zuhair M H, Razeghi S, Fazeli M, and Razavinikoo S M H. 2009. Protection of Mice by a -Based Therapeutic Vaccine against Cancer Associated with Human Papillomavirus Type 16. J Intervirol, 54:105-112.
-
Gherardi M M, Ramirez J C, and Esteban M. 2000. Interleukin-12 (IL-12) Enhancement of the Cellular Immune Response against Human Immunodeficiency Virus Type 1 Env Antigen in a DNA Prime/Vaccinia Virus Boost VaccineRegimen Is Time and Dose Dependent: Suppressive Effects of IL-12 Boost Are Mediated by Nitric Oxide. J Virol, 74: 6278-6286.
doi: 10.1128/JVI.74.14.6278-6286.2000
-
Guermonprez P, Valladeau J, Zitvogel L, Thery C, and Amigorena S. 2002. Antigen presentation and T cell stimulation by dendritic cells. J Annu Rev Immunol, 20: 621-667.
doi: 10.1146/annurev.immunol.20.100301.064828
-
Gurunathan S, Klinman D M, and Seder R A. 2000. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol, 18: 927-974.
doi: 10.1146/annurev.immunol.18.1.927
-
Ha S J, Jeon B Y, Kim S C, Kim D J, Song M K, Sung Y C, and Cho S N. 2003. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with mycobacterium tuberculosis. J Gene Ther, 10: 1543.
doi: 10.1038/sj.gt.3302042
-
Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, and Shimotohno K. 1993. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol, 67: 4665-4675.
-
Jiao X, Wang R Y, Feng Z, Hu G, Alter H J, and W-K Shih J. DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response. 2004. J Viral Hepatol, 11(1):18-26.
doi: 10.1046/j.1352-0504.2003.00464.x
-
Kim J J, Ayyavoo V, Bagarazzi M L, Chattergoon M A, Dang K, Wang B, Boyer J D, and Weiner D B. 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol, 158: 816-826.
-
Kieper W C, Tan J T, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R, and Surh C D. 2002. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J Exp Med, 195: 1533.
doi: 10.1084/jem.20020067
-
Kieper W C, Prlic M, Schmidt C S, Mescher M F, and Jameson S C. 2001. Il-12 enhances CD8+ T cell homeostatic expansion. J Immunol, 166: 5515.
doi: 10.4049/jimmunol.166.9.5515
-
Koff R S. 2003. Hepatitis vaccines: recent advances. Int J Parasitol, 33: 517-523.
doi: 10.1016/S0020-7519(03)00065-1
-
Lanford R E, Guerra B, Chavez D, Bigger C, Brasky K M, Wang X H, Ray S C, and Thomas D L. 2004. Cross-genotype immunity to hepatitis C virus. J Virol, 78(3):1575-1581.
doi: 10.1128/JVI.78.3.1575-1581.2004
-
Lang K A, Yan J, Draghia-Akli R, Khan A, and Weiner D B. 2008. Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine, 26 (49): 6225-6231.
doi: 10.1016/j.vaccine.2008.07.052
-
Lauer G M, and Walker B D. 2001. Hepatitis C virus infection. N Engl J Med, 345: 41-52.
doi: 10.1056/NEJM200107053450107
-
Martin T. 1999. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther, 10(5):759-768.
doi: 10.1089/10430349950018517
-
Nichols W W. 1995. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci, 772: 30-39.
doi: 10.1111/nyas.1995.772.issue-1
-
Semmo N, Day C L, Ward S M, Lucas M, Harcourt G, Loughry A, and Klenerman P. 2005. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. J Hepatol, 41 (5): 1019-1102.
doi: 10.1002/(ISSN)1527-3350
-
Pang P S, Jankowsky E, Planet P J, and Pyle A M. 2002. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J, 21: 1168-1176.
doi: 10.1093/emboj/21.5.1168
-
Pawlotsky J M. 2009. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol, 6(7): 383-385.
doi: 10.1038/nrgastro.2009.102
-
Schmidt C S, and Mescher M F. 1999. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD81 T cells in vivo. J Immunol, 163: 2561.
-
Scott P, and Trinchieri G. 1997. IL-12 as an adjuvant for cell-mediated immunity. Semin J Immunol, 9: 285-291.
doi: 10.1006/smim.1997.0084
-
Sin J I, Kim J J, Arnold R L, Shroff K E, McCallus D, Pachuk C, McElhiney S P, Wolf M W, Pompa-de Bruin S J, Higgins T J, Ciccarelli R B, and Weiner D B. 1999. IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse Model: IL-12 Enhances Th1-Type CD4+ T Cell-Mediated Protective Immunity against Herpes Simplex Virus-2 Challenge. J Immunol, 162: 2912-2921.
-
Shan M M, Liu K Z, Fang H L, and Chen Z. 2002. DNA immune responses induced by codelivery of IL-12 expression vectors with hepatitis C structural antigen. HBPD INT, 1(4): 553-557.
-
Tokushige K, Wakita T, Pachuk C, Moradpour D, Wener D B, Zurawski J R V R, and Wands J R. 1996. Expression and Immune Response to Hepatitis C Virus Core DNA-Based Vaccine Constructs. J Hepatol, 24:14-20.
doi: 10.1002/(ISSN)1527-3350
-
Weck K. 2005. Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn, 5 (4): 507-520.
doi: 10.1586/14737159.5.4.507
-
Weiner A J, Paliard X, Selby M J, Medina-Selby A, Coit D, Nguyen S, Kansopon Joe, L Arian Ch, Ng Ph, Tucker Jeffery, Lee Ch-T, K Polakos N, Han J, Wong Sh, Lu H-H, Rosenberg S, M Brasky K, Chien D, Kuo G, and Houghton M. 2001. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol, 75(15): 7142-7148.
doi: 10.1128/JVI.75.15.7142-7148.2001
-
Xiang Z, and Ertl H C. 1995. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. J Immunity, 2: 129-135.
doi: 10.1016/S1074-7613(95)80001-8
-
Yang S H, Lee C G, Park S H, Im S J, Kim Y M, Son J M, Wang J S, Yoon S K, Song M K, Ambrozaitis A, Kharchenko N, Yun Y D, Kim C M, Kim C Y, Lee S H, Kim B M, Kim W B, and Sung Y C. 2006. Correlation of antiviral Tcell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. J Gene Ther, 13(14): 1110-1117.
doi: 10.1038/sj.gt.3302751